This section is designed for patients and carers and for healthcare workers who wish to obtain a lay summary of this guideline. The section contains a one-page executive lay summary followed by a full lay guideline summary. The section also contains examples of patient information leaflets that can be used when initiating sodium-glucose co-transporter-2 (SGLT 2) inhibitors for people with diabetes and also for those without diabetes. It is anticipated that by providing a clear description of the contents of this guideline there will be greater understanding of the benefits and the risks of using SGLT 2 inhibitors for people with chronic kidney disease (CKD).
Navigate to sections